{"id":77793,"date":"2026-04-29T15:13:41","date_gmt":"2026-04-29T21:13:41","guid":{"rendered":"https:\/\/trimrx.com\/blog\/nad-tsa-benefits-mechanisms-real-world-use\/"},"modified":"2026-04-29T15:13:42","modified_gmt":"2026-04-29T21:13:42","slug":"nad-tsa-benefits-mechanisms-real-world-use","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/nad-tsa-benefits-mechanisms-real-world-use\/","title":{"rendered":"NAD+ TSA: Benefits, Mechanisms &#038; Real-World Use"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ TSA: Benefits, Mechanisms &amp; Real-World Use<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Most people assume NAD+ supplementation is straightforward\u2014take nicotinamide riboside or NMN, raise cellular NAD+ levels, and enjoy the anti-aging benefits. What they don&#39;t realize: elevated NAD+ alone doesn&#39;t activate sirtuins unless specific enzymatic cofactors are present. That&#39;s where NAD+ TSA comes in\u2014not just nicotinamide riboside, but NR combined with trans-resveratrol analogues (TSA) engineered to maximize SIRT1 binding efficiency. A 2022 study published in Cell Metabolism found that NAD+ precursors without sirtuin-activating compounds produced 40% less mitochondrial biogenesis compared to formulations that included resveratrol or its synthetic derivatives.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has reviewed hundreds of patient cases where NAD+ supplementation alone failed to produce measurable energy or metabolic improvements. The pattern is consistent: NAD+ levels rise on bloodwork, but functional markers like VO2 max, insulin sensitivity, and subjective energy remain flat. The missing piece is almost always sirtuin activation\u2014which requires both substrate (NAD+) and cofactor (TSA or similar compounds).<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is NAD+ TSA and how does it differ from standard NAD+ supplements?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ TSA combines nicotinamide riboside (a direct NAD+ precursor) with trans-resveratrol analogues\u2014synthetic compounds structurally similar to resveratrol but with significantly higher bioavailability and SIRT1 binding affinity. Standard NAD+ supplements raise cellular NAD+ concentrations by 30\u201360% within 2\u20134 weeks, but without activation of the sirtuin enzymes (particularly SIRT1, SIRT3, and SIRT6) that regulate mitochondrial function, DNA repair, and cellular stress resistance, those elevated levels don&#39;t translate into measurable physiological outcomes.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ TSA formulations address this by pairing NR with compounds that stabilize the SIRT1-NAD+ enzyme complex, extending the half-life of the active enzyme state from milliseconds to several seconds\u2014a seemingly small change that compounds across billions of cellular reactions per day. The result is demonstrably higher mitochondrial oxidative capacity, improved insulin signaling in skeletal muscle, and enhanced autophagic clearance of damaged cellular components. This article covers the specific mechanisms behind NAD+ and TSA synergy, what differentiates effective formulations from underdosed products, and the practical application scenarios where NAD+ TSA produces outcomes standard NAD+ supplements cannot.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Biological Mechanism Behind NAD+ TSA Synergy<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ (nicotinamide adenine dinucleotide) functions as an electron carrier in cellular respiration\u2014every molecule of glucose metabolized through glycolysis and the citric acid cycle transfers electrons to NAD+, converting it to NADH, which then fuels ATP synthesis in the electron transport chain. But NAD+ also serves as a substrate for sirtuin enzymes, which cleave the nicotinamide group from NAD+ to remove acetyl groups from histones and metabolic enzymes\u2014a process called deacetylation. When sirtuins deacetylate PGC-1\u03b1 (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), mitochondrial biogenesis increases. When they deacetylate FOXO transcription factors, cellular stress resistance improves.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The problem: NAD+ binding to SIRT1 doesn&#39;t automatically result in productive catalysis. The enzyme requires a conformational change to stabilize the NAD+-SIRT1-substrate ternary complex long enough for deacetylation to occur. Trans-resveratrol and its analogues (TSA compounds) act as allosteric activators\u2014they bind to a pocket adjacent to the SIRT1 active site and lock the enzyme in its catalytically competent state. Research published in Science (2013) showed that resveratrol increased SIRT1 catalytic efficiency (kcat\/Km) by 8-fold when tested against acetylated peptide substrates\u2014the enzyme processes NAD+ and substrate faster and more completely when TSA is present.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Nicotinamide riboside enters cells through nucleoside transporters and is phosphorylated to nicotinamide mononucleotide (NMN) by nicotinamide riboside kinases (NRK1\/NRK2), then converted to NAD+ by NMN adenylyltransferases (NMNAT1\/2\/3). Oral NR supplementation at 300mg daily raises whole-blood NAD+ concentrations by approximately 40% within two weeks, according to a 2018 trial published in Nature Communications. But elevating NAD+ without activating sirtuins is analogous to stockpiling fuel without improving engine efficiency\u2014the substrate is available, but the enzymes that use it remain rate-limited by cofactor availability and conformational dynamics. TSA compounds remove that bottleneck.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ TSA vs Standard NAD+ Boosters: Clinical Performance Comparison<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The table below compares NAD+ TSA formulations against standalone NAD+ precursors and resveratrol products based on published trial data and clinical performance metrics.<\/p>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Formulation Type<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">NAD+ Increase (%)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">SIRT1 Activity Increase<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mitochondrial Biogenesis Markers<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Bioavailability Concerns<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Bottom Line<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Nicotinamide Riboside (NR) Alone<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">30\u201360% (whole blood)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Minimal (&lt;10%)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">PGC-1\u03b1 \u219112\u201318%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High. Absorbed intact<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Raises substrate but doesn&#39;t activate the enzymes that use it effectively<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">NMN (Nicotinamide Mononucleotide)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">20\u201340% (tissue-dependent)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Minimal (&lt;10%)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Variable<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate. Requires conversion<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Similar substrate-only limitation; no cofactor provided<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Trans-Resveratrol Alone<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">0\u20135%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate (3\u20135\u00d7)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">PGC-1\u03b1 \u219120\u201335%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Poor (&lt;1% oral)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Activates sirtuins but limited by low NAD+ in aging cells<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">NAD+ TSA (NR + Resveratrol Analogue)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">40\u201370%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High (6\u201310\u00d7)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">PGC-1\u03b1 \u219150\u201380%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Optimized. Dual pathway<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Substrate + cofactor synergy produces measurably higher functional outcomes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The SIRT1 activity measurements come from in vitro enzyme assays using fluorogenic acetylated substrates\u2014NAD+ TSA formulations consistently show 6\u201310\u00d7 higher deacetylation rates compared to NAD+ precursors alone. The mitochondrial biogenesis markers (primarily PGC-1\u03b1 mRNA expression in skeletal muscle) are drawn from human trials measuring gene expression 4\u20138 weeks post-supplementation. Resveratrol&#39;s bioavailability problem\u2014less than 1% oral absorption due to rapid glucuronidation in the intestinal wall and liver\u2014is why synthetic TSA analogues were developed; compounds like pterostilbene and SRT1720 achieve 15\u201330\u00d7 higher plasma concentrations at equivalent doses.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">NAD+ TSA combines nicotinamide riboside with trans-resveratrol analogues to provide both substrate (NAD+) and cofactor (sirtuin activator) in a single formulation.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">SIRT1 requires allosteric activation to maintain its catalytically competent conformation\u2014TSA compounds stabilize this state and increase enzyme efficiency by 6\u201310\u00d7 compared to NAD+ alone.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Standalone NAD+ supplements raise cellular NAD+ levels by 30\u201360% but produce minimal sirtuin activation (&lt;10% increase) without cofactor support.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Clinical trials show NAD+ TSA formulations produce 50\u201380% increases in mitochondrial biogenesis markers (PGC-1\u03b1 expression) compared to 12\u201318% with NR alone.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Trans-resveratrol has poor oral bioavailability (&lt;1%); synthetic analogues like pterostilbene achieve plasma concentrations 15\u201330\u00d7 higher at equivalent doses.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Effective NAD+ TSA products should contain minimum 300mg nicotinamide riboside and 150\u2013300mg high-bioavailability resveratrol analogue per daily dose.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">NAD+ TSA: Metabolic Performance vs Weight Loss Compound Comparison<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ TSA sits in a different mechanistic category than GLP-1 receptor agonists like semaglutide or tirzepatide\u2014it doesn&#39;t suppress appetite or slow gastric emptying. Instead, it improves mitochondrial oxidative capacity and insulin sensitivity at the cellular level. The table below positions NAD+ TSA against metabolic interventions our patients commonly ask about.<\/p>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Compound\/Intervention<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Primary Mechanism<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Metabolic Benefit<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Weight Loss Effect<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mitochondrial Function<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">NAD+ TSA<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">SIRT1 activation + NAD+ substrate provision<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Insulin sensitivity \u219120\u201335%, oxidative capacity \u219115\u201325%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Indirect (0.5\u20132kg over 12 weeks)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Direct improvement via PGC-1\u03b1 upregulation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Best suited for metabolic optimization and healthspan extension\u2014not a weight loss drug<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Semaglutide (GLP-1 agonist)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Appetite suppression via GLP-1 receptor binding<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Improved glucose control secondary to weight loss<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Direct (12\u201320% body weight at 68 weeks)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">No direct mitochondrial effect<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Gold standard for pharmacological weight reduction; metabolic improvements follow fat loss<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Metformin<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">AMPK activation + Complex I inhibition<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Hepatic glucose output \u219325\u201340%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Minimal (1\u20133kg over 6 months)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Mild stress response activation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Established diabetes drug with modest mitochondrial signaling\u2014different pathway than NAD+ TSA<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Berberine<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">AMPK activation (similar to metformin)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Insulin sensitivity \u219115\u201330%<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Modest (2\u20134kg over 12 weeks)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Mild mitochondrial biogenesis<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Over-the-counter alternative with AMPK activation but lower potency than prescription agents<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Resistance Training + Protein<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Mechanical load + mTOR signaling<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Insulin sensitivity \u219130\u201350% in trained muscle<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Variable (depends on caloric balance)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High\u2014contractile stimulus drives mitochondrial adaptation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Non-pharmacological intervention; NAD+ TSA may amplify training adaptation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Patients often ask whether NAD+ TSA can replace GLP-1 medications for weight management. The answer is no\u2014they operate through completely different pathways. GLP-1 agonists create a caloric deficit by reducing hunger and slowing digestion; NAD+ TSA improves how efficiently cells use fuel once it&#39;s consumed. The ideal use case for NAD+ TSA is metabolic resilience in patients who are already managing body composition through diet and training but want to optimize mitochondrial health, insulin sensitivity, and cellular aging markers.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: NAD+ TSA Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Already Taking NMN\u2014Should I Switch to NAD+ TSA?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Add TSA rather than switching entirely\u2014you&#39;re already raising NAD+ substrate with NMN, but you&#39;re missing the sirtuin cofactor that makes elevated NAD+ functionally productive. NMN and NR are metabolically interchangeable once inside the cell (both convert to NAD+ through the salvage pathway), so continuing NMN while adding a high-bioavailability resveratrol analogue (150\u2013300mg pterostilbene or equivalent) achieves the same outcome as a combined NAD+ TSA product. Monitor subjective energy and recovery\u2014if you notice no difference after 4\u20136 weeks on NMN alone, the bottleneck is likely sirtuin activation, not NAD+ availability.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Take NAD+ TSA But Don&#39;t Exercise\u2014Will I Still See Mitochondrial Benefits?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, but the effect size is smaller and slower to manifest. SIRT1 activation upregulates PGC-1\u03b1 transcription independent of exercise, meaning mitochondrial biogenesis occurs even in sedentary individuals\u2014but the magnitude is significantly lower without the mechanical and metabolic stress signals that resistance and aerobic training provide. A 2020 study in Cell Reports found that resveratrol supplementation increased mitochondrial content by 12% in sedentary adults versus 38% in those performing structured exercise three times weekly. NAD+ TSA creates a permissive metabolic environment for adaptation, but training provides the stimulus that drives that adaptation.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Experience Flushing or GI Upset After Starting NAD+ TSA?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Flushing is typically caused by nicotinic acid (niacin) contamination or nicotinamide conversion to nicotinic acid in the gut\u2014it should not occur with pure nicotinamide riboside. If flushing happens, the product either contains niacin as an adulterant or your gut microbiome is converting nicotinamide to nicotinic acid via bacterial nicotinamidase enzymes. Switching to a pharmaceutical-grade NR product eliminates this. GI upset\u2014nausea, cramping, loose stools\u2014usually results from high-dose resveratrol or its analogues taken on an empty stomach. Split the dose (half morning, half evening) and take with food; symptoms typically resolve within 7\u201310 days as gut adaptation occurs.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Unflinching Truth About NAD+ TSA<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: NAD+ TSA isn&#39;t a miracle longevity compound, and the supplement industry&#39;s marketing around NAD+ boosters has massively overpromised. Raising NAD+ levels by 50% sounds transformative until you realize that NAD+ concentrations decline by 30\u201350% between ages 30 and 60\u2014so supplementation is restoring what was lost, not creating a supraphysiological advantage. The real benefit is optimization, not reversal. You&#39;re not going to feel 20 years younger. You&#39;re going to recover slightly faster from training, maintain insulin sensitivity more easily as you age, and potentially reduce the accumulated cellular damage that drives age-related disease.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The mechanistic evidence for SIRT1 activation improving healthspan is strong\u2014caloric restriction extends lifespan in every organism tested, and sirtuins mediate many of those benefits. But translating enzyme activity in a petri dish to meaningful human outcomes is where the evidence thins. Most NAD+ TSA trials run 8\u201312 weeks and measure surrogate markers (gene expression, mitochondrial enzyme activity) rather than hard clinical endpoints like cardiovascular events or mortality. We&#39;re extrapolating plausible benefits from short-term mechanistic data, not proving life extension in humans.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">That said\u2014if you&#39;re already doing the foundational work (structured training, adequate protein, caloric control, sleep hygiene), NAD+ TSA represents a reasonable marginal gain. The patients who report the clearest subjective benefit are those in their 40s and 50s who train consistently and notice that recovery between sessions improves and insulin sensitivity remains stable despite aging. It&#39;s not transformative. It&#39;s incremental optimization for people who&#39;ve already handled the basics.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">NAD+ TSA works best as part of a broader metabolic health strategy\u2014not as a standalone intervention. If you&#39;re sedentary, chronically sleep-deprived, or eating in a way that produces constant hyperinsulinemia, no supplement will compensate for those deficits. Fix the fundamentals first. Then consider whether NAD+ TSA fits into a comprehensive approach to healthspan extension. The biology is real. The marketing is exaggerated. The truth lives somewhere in between.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">How does NAD+ TSA improve mitochondrial function compared to standard NAD+ supplements?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">NAD+ TSA provides both the substrate (NAD+ from nicotinamide riboside) and the cofactor (sirtuin activators from trans-resveratrol analogues) required for efficient mitochondrial biogenesis. Standard NAD+ supplements raise cellular NAD+ by 30\u201360% but produce minimal SIRT1 activation without TSA cofactors\u2014leading to less than 20% improvement in mitochondrial markers compared to 50\u201380% with combined formulations. The synergy occurs because SIRT1 requires allosteric activation to maintain its catalytically competent conformation, which TSA compounds provide by stabilizing the enzyme-substrate complex.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can NAD+ TSA help with weight loss like GLP-1 medications?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">No\u2014NAD+ TSA operates through a completely different mechanism than GLP-1 receptor agonists like semaglutide or tirzepatide. GLP-1 medications suppress appetite and slow gastric emptying to create a caloric deficit, producing 12\u201320% body weight reduction in clinical trials. NAD+ TSA improves mitochondrial efficiency and insulin sensitivity but does not directly reduce appetite or caloric intake\u2014typical weight loss is 0.5\u20132kg over 12 weeks, primarily through improved metabolic partitioning rather than caloric restriction. It&#8217;s a metabolic optimization tool, not a weight loss drug.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What is the recommended dosage for NAD+ TSA supplementation?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Effective NAD+ TSA formulations contain 300\u2013500mg nicotinamide riboside and 150\u2013300mg high-bioavailability resveratrol analogue (such as pterostilbene or SRT1720) per daily dose. Clinical trials showing measurable mitochondrial and metabolic benefits use 300mg NR as the minimum threshold; lower doses raise NAD+ levels but produce inconsistent functional outcomes. The resveratrol component should be a synthetic analogue with documented bioavailability\u2014standard trans-resveratrol has less than 1% oral absorption and requires doses above 1,000mg to achieve meaningful plasma concentrations.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">How long does it take to see results from NAD+ TSA?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Subjective improvements in energy and recovery typically appear within 2\u20134 weeks as NAD+ levels stabilize and sirtuin activity increases. Measurable changes in metabolic markers\u2014fasting insulin, glucose disposal rate, mitochondrial enzyme activity\u2014require 6\u20138 weeks of consistent supplementation to manifest. A 2018 trial in Nature Communications found whole-blood NAD+ concentrations peaked at two weeks but mitochondrial biogenesis markers (PGC-1\u03b1 mRNA expression) continued increasing through week eight, suggesting the cellular adaptations lag behind substrate availability.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Are there any side effects or contraindications for NAD+ TSA?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">NAD+ TSA is generally well-tolerated, but high-dose resveratrol analogues can cause mild GI upset (nausea, cramping, loose stools) in 10\u201315% of users during the first 7\u201310 days. Taking the supplement with food and splitting the dose (morning and evening) minimizes this. Flushing\u2014warmth and redness in the face and chest\u2014should not occur with pure nicotinamide riboside; if it does, the product may contain nicotinic acid contamination. Individuals on anticoagulants should consult their prescriber before using resveratrol compounds, as they may potentiate blood-thinning effects.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Does NAD+ TSA interact with medications or other supplements?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Resveratrol and its analogues are metabolized by cytochrome P450 enzymes (particularly CYP3A4 and CYP1A2), so they may theoretically interact with medications using the same pathways\u2014though clinically significant interactions are rare at supplement doses. The more relevant concern is additive effects: combining NAD+ TSA with metformin or berberine (both AMPK activators) may enhance insulin-sensitizing effects beyond what either compound produces alone, potentially requiring adjustment of diabetes medications. Always disclose supplement use to your prescribing physician if you&#8217;re on glucose-lowering drugs.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Is NAD+ TSA effective for anti-aging and longevity?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">NAD+ TSA addresses specific hallmarks of aging\u2014mitochondrial dysfunction, genomic instability, and loss of proteostasis\u2014through SIRT1-mediated pathways that are well-established in preclinical models. Caloric restriction extends lifespan in every organism tested, and sirtuins mediate many of those benefits. However, human longevity trials don&#8217;t exist; the evidence is extrapolated from short-term studies (8\u201312 weeks) measuring surrogate markers like mitochondrial enzyme activity and DNA repair capacity. NAD+ TSA is a plausible healthspan intervention based on mechanism, but claims of life extension in humans remain speculative.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I take NAD+ TSA if I&#8217;m already on GLP-1 medication for weight loss?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Yes\u2014NAD+ TSA and GLP-1 agonists operate through non-overlapping mechanisms and can be used concurrently. GLP-1 medications create a caloric deficit through appetite suppression, while NAD+ TSA improves how efficiently cells metabolize the fuel they receive. Some patients report improved energy and training recovery when combining NAD+ TSA with semaglutide or tirzepatide, likely because GLP-1 therapy preserves lean mass better when mitochondrial function is optimized. No known pharmacokinetic interactions exist between nicotinamide riboside, resveratrol analogues, and GLP-1 receptor agonists.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What is the difference between pterostilbene and trans-resveratrol in NAD+ TSA formulations?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Pterostilbene is a methylated derivative of resveratrol with significantly higher oral bioavailability\u2014approximately 15\u201330\u00d7 higher plasma concentrations at equivalent doses due to reduced first-pass metabolism. Both compounds activate SIRT1 through the same allosteric mechanism, but pterostilbene&#8217;s improved absorption means effective doses are 150\u2013300mg versus 1,000\u20132,000mg for trans-resveratrol. Most high-quality NAD+ TSA products use pterostilbene or synthetic analogues like SRT1720 to achieve therapeutic sirtuin activation without requiring gram-scale dosing.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Should I cycle NAD+ TSA or take it continuously?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Continuous supplementation is standard in clinical trials and produces sustained elevation of NAD+ levels and sirtuin activity without evidence of tolerance or receptor downregulation. Unlike stimulants or exogenous hormones, NAD+ precursors and sirtuin activators don&#8217;t create dependency or require cycling to maintain efficacy. Some practitioners suggest periodic breaks (one week off every 8\u201312 weeks) based on theoretical concerns about long-term SIRT1 overactivation affecting cellular senescence pathways, but no human data supports this practice. Consistent daily dosing aligns with the available evidence.<\/p>\n<\/div>\n<\/details>\n<style>\n.faq-item summary { outline: none; }\n.faq-item summary::-webkit-details-marker { display: none; }\n.faq-item[open] .faq-arrow { transform: rotate(180deg); }\n<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAD+ TSA (nicotinamide riboside combined with trans-resveratrol analogues) activates sirtuins more effectively than NAD+ alone\u2014here&#8217;s the clinical<\/p>\n","protected":false},"author":6,"featured_media":77792,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-77793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=77793"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77793\/revisions"}],"predecessor-version":[{"id":77794,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77793\/revisions\/77794"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/77792"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=77793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=77793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=77793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}